Evidence map›Paper›PMID 20876671›Full record

SynthesisClinical journal of the American Society of Nephrology : CJASN2011

Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials.

Praveen Kandula, Mirela Dobre, Jesse D Schold, Martin J Schreiber, Rajnish Mehrotra, Sankar D Navaneethan

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Clinical journal of the American Society of Nephrology : CJASN, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
119citing papers in PubMed, 5 pooled it
14.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

119 citing papers in PubMed, 5 syntheses or guidelines pooled it, 295 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Nutritional vitamin D supplementation in dialysis: a randomized trial.Clinical journal of the American Society of Nephrology : CJASN · 2015
    Trial
  11. Trial
  12. Review
  13. Article
  14. Current Controversies on Adequate Circulating Vitamin D Levels in CKD.International journal of molecular sciences · 2025
    Review
  15. Article
  16. Vitamin D: are all compounds equal?Clinical kidney journal · 2025
    Article
  17. Review
  18. Review
  19. Review
  20. Review

59 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Praveen KandulaDepartment of Nephrology, Indiana University, Indianapolis, Indiana, USA.
Mirela Dobre
Jesse D Schold
Martin J Schreiber
Rajnish Mehrotra
Sankar D Navaneethan
Kidney Centre · PKCase Western Reserve University · USCleveland Clinic · USIndiana University – Purdue University Indianapolis · USLos Angeles Medical Center · US

Funding

Case Western Reserve University/Cleveland Clinic CTSA (KL2)KL2RR024990 · NCRR · CASE WESTERN RESERVE UNIVERSITY · PI DAVIS, PAMELA B · 2007 to 2011
$9.5M
NCRR NIH HHS KL2 RR024990NCRR NIH HHS RR024990
6 · The paper itself

Abstract

BACKGROUND AND

objectivesVitamin D deficiency is highly prevalent among patients with chronic kidney disease (CKD). The benefits and harms of vitamin D supplementation (ergocalciferol or cholecalciferol) were assessed in patients with nondialysis-dependent CKD, dialysis-dependent CKD, and renal transplant recipients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: MEDLINE (1966 to September 2009), SCOPUS (September 2009), and nephrology conference proceedings were searched for relevant observational and randomized controlled trials (RCTs). Treatment effects were summarized as mean differences (MDs) with 95% confidence intervals (CIs) using a random effects model. Separate analyses were conducted for observational studies and RCTs.

resultsTwenty-two studies (17 observational and 5 RCTs) were included. There was a significant improvement in 25-hydroxyvitamin D (MD 24.1 ng/ml, 95% CI 19.6 to 28.6) and an associated decline in parathyroid hormone (PTH) levels (MD -41.7 pg/ml, 95% CI -55.8 to -27.7) among observational studies. PTH reduction was higher in dialysis patients. Among RCTs, there was a significant improvement in 25-hydroxyvitamin D (MD 14 ng/ml, 95% CI 5.6 to 22.4) and an associated decline in PTH levels (MD -31.5 pg/ml, 95% CI -57 to -6.1). A low incidence of hypercalcemia and hyperphosphatemia was reported with vitamin D supplementation. Cardiovascular and skeletal effects of vitamin D supplementation have not been studied. Included studies were mostly of low to moderate quality.

conclusionsAvailable evidence from low-to-moderate quality observational studies and fewer RCTs suggests that vitamin D supplementation improves biochemical endpoints. However, whether such improvements translate into clinically significant outcomes is yet to be determined.

Indexed as

CalciumChronic DiseaseDietary SupplementsFibroblast Growth Factor-23Fibroblast Growth FactorsKidney DiseasesKidney Failure, ChronicParathyroid HormonePhosphorusRandomized Controlled Trials as TopicVitamin D25-hydroxyvitamin DCalciumFibroblast Growth Factor-23Fibroblast Growth FactorsParathyroid HormonePhosphorusVitamin D

Identifiers

PMID20876671
PMCPMC3022248
OpenAlexW2162443675

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.